Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Operational Highlights
TMO logo

Thermo Fisher Boosts Revenue 5% on Bioproduction Surge, Eyes $9B Clario Deal

TMO10-QFiling Date: 10/31/2025
Thermo Fisher Scientific Inc.
Description

What this story covers

Thermo Fisher Scientific's Q3 2025 10-Q shows 5% revenue growth to $10.64B, driven by 3% organic gains in bioproduction amid softer academic demand. Key segments advanced, margins expanded. Pending $9B Clario acquisition enhances clinical trials; strong liquidity supports buybacks and capex. Restructuring streamlines operations; risks are mitigated.

Story snapshot

CompanyThermo Fisher Scientific Inc.
TickerTMO
VariantStandard detailed
Duration11:39
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0000097745-25-000159

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in